Nalaganje...
Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer
In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mut...
Shranjeno v:
| izdano v: | Front Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5712561/ https://ncbi.nlm.nih.gov/pubmed/29238696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00288 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|